Delayed transfusion reactions and alloimmunisation

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Delayed reactions are easily missed because the patient has left the transfusion area and the falling haemoglobin may be attributed to illness. Ask about transfusion in the preceding weeks whenever anaemia, jaundice, dark urine, fever, pain or an unexpected laboratory change develops. Obtain the pretransfusion and immediate post-transfusion haemoglobin when available and contact the transfusion laboratory before ordering more blood. A normal antibody screen before the original event does not exclude an antibody that was below detection.

Delayed haemolytic transfusion reaction usually reflects an anamnestic alloantibody. Pregnancy or an earlier transfusion created immune memory; antibody concentration then waned, antigen-positive donor cells were selected during a later negative screen and memory response cleared them over days. Kidd antibodies are a classic example of evanescence, but Rh, Kell, Duffy and other clinically significant specificities also cause reactions. Extravascular macrophage clearance is common, although brisk intravascular or mixed haemolysis can occur.

Investigate by trending full blood count and reticulocytes and measuring bilirubin, LDH, haptoglobin, renal function and urine haemoglobin. Repeat ABO and antibody testing and perform a DAT; the laboratory may elute antibody from coated cells, re-crossmatch the implicated unit segment and phenotype or genotype the patient. Mixed donor and patient cells can complicate phenotyping soon after transfusion, making genotype valuable. A negative DAT or incomplete biochemical pattern does not remove the diagnosis when timing and a newly identified antibody fit.

Most uncomplicated delayed haemolytic reactions need supportive care and avoidance of further incompatible exposure rather than aggressive treatment. Assess renal function, symptoms and cardiovascular tolerance and treat the underlying anaemia. If blood is still required, the laboratory selects red cells negative for all current and historical clinically significant antigens, with reference-centre support when necessary. Document the antibody permanently and inform the patient, because the next emergency may occur at a different hospital after the antibody again becomes undetectable.

Hyperhaemolysis is a distinct emergency, particularly in sickle-cell disease. Both donor and autologous cells are destroyed, haemoglobin falls below its pretransfusion baseline and reticulocytes are often unexpectedly low. Pain and haemoglobinuria can mimic vaso-occlusive illness. Additional transfusion may intensify haemolysis, so avoid it unless anaemia threatens life and involve a sickle specialist and transfusion consultant. Immunomodulatory treatment is protocol and severity dependent; obtain optimally matched units and critical-care support when transfusion is unavoidable.

Post-transfusion purpura causes an abrupt, often profound platelet fall 5–12 days after transfusion, most often through an anamnestic HPA antibody. Bleeding ranges from purpura to intracranial haemorrhage. Send HPA antibody and genotyping investigations through the transfusion laboratory, but do not await confirmation before specialist high-dose IVIG when the phenotype is compelling. Random platelets are often ineffective and can add antigen; reserve HPA-compatible platelets for life-threatening bleeding with expert coordination.

TA-GVHD is rare but usually fatal. Viable donor T lymphocytes engraft when the recipient cannot reject them or when donor-recipient HLA similarity permits escape. Fever, rash, watery diarrhoea, hepatitis and progressive pancytopenia typically occur 1–2 weeks after transfusion. Skin or gut biopsy and donor-cell chimerism can support diagnosis, but treatment success is limited. Prevention is the central strategy: irradiate cellular components for defined recipients and directed donations from relatives; leucodepletion alone is inadequate.

Other delayed burdens include alloimmunisation without haemolysis and transfusional iron overload. Regularly transfused sickle-cell and thalassaemia patients need disease-specific antigen matching, cumulative unit records and screening before each episode. Ferritin is useful longitudinally but is confounded by inflammation; liver and cardiac MRI quantify tissue iron when indicated. Chelation choice and dose are specialist decisions based on transfusion burden, organ iron, kidney and liver function, adverse effects and reproductive plans.

Key points

Delayed haemolytic transfusion reaction occurs more than 24 hours after transfusion, usually within days to several weeks, with haemolysis and a new or re-emergent red-cell antibody.
Key clues are failure of the expected haemoglobin increment, a later haemoglobin fall, jaundice, dark urine, fever, pain, bilirubin or LDH rise, low haptoglobin and a new positive DAT.
Confirmatory assessment combines repeat antibody screen and identification, DAT and eluate where appropriate, repeat crossmatch and antigen typing of patient and implicated units.
A delayed serological transfusion reaction means a new antibody or serological incompatibility without clinical or biochemical haemolysis.
Historical clinically significant antibodies remain binding even when the current screen is negative; future red cells must lack the corresponding antigen.
Hyperhaemolysis destroys transfused and autologous cells, causing haemoglobin below baseline and often reticulocytopenia; avoid further transfusion unless life saving.
First-line hyperhaemolysis management is urgent sickle or haematology specialist-led immunomodulation and supportive care, with further red cells reserved for critical anaemia.
Post-transfusion purpura presents with severe thrombocytopenia and bleeding about 5–12 days after transfusion; high-dose intravenous immunoglobulin is first-line specialist treatment.
TA-GVHD presents about 1–2 weeks after transfusion with fever, rash, diarrhoea, liver dysfunction and pancytopenia and has very high mortality.
Irradiation prevents TA-GVHD by disabling donor lymphocyte proliferation; leucodepletion and CMV-negative selection do not replace irradiation.
Reduce alloimmunisation by avoiding unnecessary transfusion and using disease-specific extended antigen matching for chronically transfused patients.
Give the patient antibody and special-component information, update permanent laboratory records and communicate requirements across hospitals, pregnancies and emergency care.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Anamnestic red-cell alloantibody

A previously formed antibody can fall below screening detection and expand rapidly after transfusion of antigen-positive donor cells, causing a delayed haemolytic reaction.

Primary alloimmunisation

Pregnancy or transfusion exposes a recipient to non-self red-cell antigens, generating a new antibody that may first appear after the implicated transfusion.

Platelet alloantibody

Post-transfusion purpura usually reflects an anamnestic antibody to a human platelet antigen, classically HPA-1a, with destruction of donor and recipient platelets.

Viable donor lymphocytes

Non-irradiated cellular components can transfer T lymphocytes that engraft and attack recipient tissues when immune recognition or clearance is impaired.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Extravascular donor-cell clearance
IgG alloantibody coats antigen-positive donor red cells, which splenic and hepatic macrophages remove, producing jaundice, LDH rise and loss of the expected haemoglobin increment.
2
Hyperhaemolysis
Immune and complement dysregulation can destroy transfused and autologous red cells, driving haemoglobin below the pretransfusion level and often suppressing the reticulocyte response.
3
Alloantibody evanescence
Antibody concentrations decline over time and may become screen negative, yet memory B cells persist and can react briskly with later antigen exposure.
4
Donor lymphocyte engraftment
In transfusion-associated graft-versus-host disease, proliferating donor T cells attack skin, gut, liver and marrow, producing rash, diarrhoea, hepatitis and fatal pancytopenia.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Delayed haemolytic reaction

Jaundice, dark urine and haemoglobin loss after 24 hours with a new antibody, DAT change or incompatible retrospective crossmatch.

Delayed serological reaction

A new antibody or DAT appears after transfusion without symptoms, haemoglobin loss or biochemical evidence of haemolysis.

Hyperhaemolysis

Post-transfusion haemoglobin falls below baseline with destruction of donor and autologous cells and often an inappropriately low reticulocyte count.

Post-transfusion purpura

Sudden profound thrombocytopenia and bleeding about 5–12 days after transfusion, often in a previously sensitised patient.

TA-GVHD

Fever, rash, diarrhoea, liver injury and marrow failure one to two weeks after a non-irradiated cellular component.

Iron overload

Cumulative transfusion produces rising tissue iron, liver injury, endocrine dysfunction or cardiomyopathy over months to years rather than an acute reaction.

Red flags requiring action

A haemoglobin fall below the pretransfusion value with pain, haemoglobinuria or reticulocytopenia suggests hyperhaemolysis, particularly in sickle-cell disease.
Fever, maculopapular rash, diarrhoea, hepatitis and pancytopenia 1–2 weeks after cellular transfusion is TA-GVHD until urgently excluded.
Profound thrombocytopenia with bleeding 5–12 days after transfusion suggests post-transfusion purpura and requires same-day haematology and transfusion consultation.
Jaundice, dark urine, back pain or an unexplained loss of haemoglobin within days to weeks after transfusion requires a delayed-haemolysis screen.
A new clinically significant antibody during pregnancy can threaten the fetus and must enter the specialist obstetric antibody pathway as well as the transfusion record.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line: full blood count and reticulocytesFirst stepFirst line
Why
Measure red-cell or platelet loss and marrow response.
Interpretation and limitations
Falling haemoglobin with reticulocytosis supports haemolysis; haemoglobin below baseline with reticulocytopenia raises hyperhaemolysis; profound platelet loss suggests purpura.
02
First-line: haemolysis screenFirst line
Why
Confirm accelerated red-cell destruction and organ effect.
Interpretation and limitations
Bilirubin and LDH rise, haptoglobin falls and urine may contain haemoglobin; renal dysfunction and potassium elevation mark severe disease.
03
Repeat antibody screen, identification and DAT
Why
Demonstrate a new or re-emergent alloantibody and red-cell coating.
Interpretation and limitations
Compare with the pretransfusion sample and history; eluate and retrospective unit crossmatch can define specificity even when plasma testing is weak.
04
Red-cell phenotype or genotype
Why
Select antigen-negative units and plan extended matching.
Interpretation and limitations
Recent donor cells can distort phenotype, while molecular genotype remains informative and supports chronic transfusion planning.
05
HPA antibody and platelet genotype
Why
Confirm post-transfusion purpura and identify compatible platelet support.
Interpretation and limitations
Send through the transfusion laboratory, but a clinically severe case receives specialist treatment before reference results return.
06
Biopsy and chimerism for TA-GVHD
Why
Distinguish donor lymphocyte injury from infection, drug eruption or disease relapse.
Interpretation and limitations
Compatible skin or gut histology and donor lymphocyte chimerism support diagnosis; urgent management and reporting proceed on clinical suspicion.
07
Ferritin trend and organ MRI
Why
Assess chronic transfusional iron accumulation.
Interpretation and limitations
Ferritin trends exposure but rises with inflammation; liver iron concentration and cardiac T2-star MRI guide organ-specific chelation strategy.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Autoimmune or mechanical haemolysis

Warm autoantibody, cold disease, microangiopathy, valve-related destruction, infection and oxidant injury can cause the same bilirubin, LDH and haemoglobin pattern.

Bleeding or dilution

Occult haemorrhage, perioperative loss and fluid expansion can erase the expected post-transfusion increment without immune red-cell destruction.

Relapse, infection or drug toxicity

Fever, rash, diarrhoea, hepatitis and cytopenias after treatment may reflect sepsis, viral infection, engraftment syndrome or medicine toxicity rather than TA-GVHD.

ITP, DIC or TTP

Severe post-transfusion thrombocytopenia can arise from immune thrombocytopenia, consumption, microangiopathy or HIT; the interval and HPA investigation help identify purpura.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Suspected delayed haemolysisConfirm destruction and preserve compatibilityFirst stepHaemoglobin falls or jaundice develops more than 24 hours after transfusion.

1Send FBC, reticulocytes, bilirubin, LDH, haptoglobin, renal profile, urine and a new compatibility sample and call the transfusion laboratory.
2Repeat antibody identification, DAT and retrospective compatibility work, retrieving external and historical antibody records.
3Provide supportive care and only antigen-negative crossmatch-compatible red cells if still necessary; document the antibody permanently.

02Suspected hyperhaemolysisAvoid amplifying cell destructionHaemoglobin is below pretransfusion baseline with haemolysis and reticulocytopenia, particularly in sickle-cell disease.

1Obtain urgent sickle, haematology and transfusion-consultant input and monitor for cardiovascular or renal compromise.
2Avoid further red cells unless anaemia is life threatening; start specialist immunomodulation and optimise erythropoietic support under protocol.
3If transfusion is unavoidable, use the most extensively matched available units with critical-care monitoring and repeated haemolysis assessment.

03Post-transfusion purpuraTreat immune platelet destruction urgentlyProfound thrombocytopenia with bleeding appears 5–12 days after transfusion.

1Send count confirmation, film, coagulation and HPA antibody and genotype samples and exclude DIC, TTP, HIT and medicines.
2Start high-dose IVIG under urgent haematology and transfusion guidance without waiting for reference results when clinical suspicion is strong.
3Reserve HPA-compatible platelet support for life-threatening bleeding and record the antibody for all future transfusions.

04Possible TA-GVHDEscalate a preventable lethal syndromeEscalationFever, rash, diarrhoea, liver dysfunction and cytopenias emerge after transfusion.

1Contact haematology, transfusion medicine, microbiology and critical care and institute protective infection management.
2Send marrow, viral and chimerism investigations and obtain skin or gut biopsy where safe without delaying supportive treatment.
3Report urgently, trace implicated components and review whether irradiation indications were recognised and communicated.

05Alloimmunisation preventionReduce exposure and match prospectivelyPregnancy, chronic transfusion or an existing antibody creates high future risk.

1Avoid unnecessary units and ensure complete antibody, pregnancy and transfusion history is available before selection.
2Use antigen-negative cells for every current and historical antibody and disease-specific extended matching for haemoglobinopathies.
3Give durable patient information and share special requirements across laboratory networks, clinical correspondence and pregnancy records.

Key medicines and prescribing safety1 treatment · regimens, roles and cautions

First-line specialist treatment that usually raises the platelet count rapidly in clinically significant post-transfusion purpura.

Intravenous immunoglobulin for post-transfusion purpura

Give a total of 1 to 2 g/kg intravenously in divided doses over 2 to 5 days under a consultant haematology and transfusion protocol; use the dosing weight required by the commissioned immunoglobulin policy.

Ensure adequate hydration and use the recommended infusion rate. Review thrombosis, hyperviscosity, haemolysis, aseptic meningitis and renal risk; select an appropriate preparation in renal impairment or diabetes and monitor creatinine, urine output and haemolysis. Discuss pregnancy with haematology and obstetrics but do not withhold life-saving treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Severe anaemia and organ hypoxia

Accelerated donor and autologous red-cell destruction can cause cardiovascular compromise, renal injury and a need for difficult emergency transfusion.

Future compatibility delay

Multiple or rare alloantibodies narrow the donor pool, prolong reference testing and complicate emergency, surgical and pregnancy support.

Critical haemorrhage from purpura

Profound thrombocytopenia after post-transfusion purpura can cause gastrointestinal, mucosal or intracranial bleeding and may worsen with ineffective platelet exposure.

Fatal marrow aplasia

TA-GVHD destroys recipient haematopoiesis; profound pancytopenia and infection follow, treatment is rarely successful and prevention by irradiation is essential.

Iron-mediated organ damage

Repeated red-cell transfusion deposits iron in liver, heart and endocrine organs, causing fibrosis, cardiomyopathy, diabetes and hypogonadism without adequate chelation.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Trend haemoglobin, reticulocytes, bilirubin, LDH, haptoglobin, creatinine and urine output until haemolysis has clearly resolved.
After any necessary additional transfusion in hyperhaemolysis, monitor closely for pain, haemoglobinuria, reticulocyte suppression and a renewed fall below baseline.
In post-transfusion purpura, measure platelets at least daily during severe thrombocytopenia and assess actively for neurological, gastrointestinal and mucosal bleeding.
In suspected TA-GVHD, trend FBC, liver tests, diarrhoea, rash, fever and cultures and manage neutropenic infection risk continuously.
Maintain permanent antibody and special-component records and verify that discharge letters, patient alerts and future pregnancy care contain them.
For chronic transfusion, monitor cumulative units, ferritin trend, liver and cardiac iron imaging, endocrine function and chelation toxicity under the disease programme.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

A negative screen forgets concentration, not memory

Evanescent antibodies can be undetectable while memory B cells remain capable of a clinically important anamnestic response.

Compare with the pretransfusion baseline

Hyperhaemolysis is recognised by destruction beyond the donor increment, with haemoglobin falling below where the patient began.

Reticulocytes change the interpretation

An inappropriately low count during severe haemolysis supports hyperhaemolysis or marrow suppression and argues against simply giving more red cells.

Leucodepletion is not irradiation

Filtering reduces white-cell number but does not reliably prevent the residual viable T lymphocytes from proliferating and causing TA-GVHD.

Alloantibodies cross institutions poorly

Laboratory records are not universally shared, so patient cards and explicit clinical correspondence can prevent an incompatible emergency exposure.

Ferritin is a trend, not tissue

Inflammation changes ferritin independently of iron, while MRI directly estimates liver and cardiac deposition for specialist treatment decisions.

11Common pitfallsFrequent interpretation and management errors.

01
Do not dismiss a post-transfusion haemoglobin fall because the pretransfusion antibody screen was negative.
02
Do not ignore a historical antibody after it becomes undetectable.
03
Do not repeatedly transfuse presumed hyperhaemolysis without specialist review; more red cells can worsen destruction.
04
Do not interpret a negative DAT as absolute exclusion of delayed haemolysis.
05
Do not give random platelets reflexively in post-transfusion purpura when there is no life-threatening bleeding.
06
Do not confuse leucodepleted, CMV-negative and irradiated components; each modification addresses a different risk.
07
Do not overlook TA-GVHD when fever and rash are initially labelled sepsis or drug allergy.
08
Do not rely on ferritin alone to quantify chronic organ iron.
09
Do not keep antibody information only in one hospital's laboratory system.